Talk Radioisotopes: 2025 Top Podcasts #2

The Talk Radioisotopes podcast debuted in January 2025. To mark the end of the 2025 calendar year, we’re counting down the top three most listened/downloaded episodes of the show. Coming in at #2 is Oppenheimer’s Jeff Jones.

I think one thing that's highlighted is really the move of large pharma into the space. And now that rather than just really having Novartis on there, we now have several large pharmas on there starting to build portfolios. And I think the other thing that's noticeable there is there's a grouping of some late stage products and only obviously Pluvicto and Lutathera on the market, and a lot of really early stage programs at the preclinical level, which typically as an equity research analyst, we probably wouldn't even look at preclinical. But in this space, we have to because the space is relatively early. So you've got this big gap in phase one data, phase two data, and the assets. And I think that's one of the things we're really excited about looking into next year is as these assets start to mature.

Full Episode